|Bid||2.0200 x 1200|
|Ask||2.2800 x 1800|
|Day's Range||2.0800 - 2.2800|
|52 Week Range||0.6660 - 3.9300|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. ("LyGenesis"), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement for a merger of the two companies. LyGenesis recently received U.S. Food and Drug Administration clearance for its Investigational New Drug application to conduct a Phase 2a clinical trial on the safety, tolerability, and efficacy of its lead cell therapy for patients with end-stage liver disease, with study initiation planned for 2021. The combined company’s pipeline would also include thymus, pancreas, and kidney regeneration, in addition to the existing AgeX assets, including UniverCyte™, which uses the HLA-G gene to potentially confer low immune observability to cells to suppress rejection of transplanted cells.
AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting of Stockholders (the "Annual Meeting") to be held at 10:00 a.m. Pacific Standard Time on Monday, December 28, 2020 will be permitted only through online participation. The County of Alameda, California, where AgeX’s offices are located and where AgeX had planned to hold the Annual Meeting, has issued Health Officer Order 20-21 (the "Order") restricting or prohibiting many business activities due to the COVID-19 pandemic. The Order provides that offices must close and business must be conducted remotely, except in critical infrastructure sectors where remote work is not possible.
AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, reported financial and operating results for the third quarter ended September 30, 2020.